Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Simpson

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
European Journal of Dermatology : EJD|October 27, 2022
Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trialsAndreas Wollenberg, Peter Lio, Elise Kleyn, et al.
Dermatology and Therapy|November 12, 2024
Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b StudyMelinda Gooderham, Emma Guttman-Yassky, Ken Igawa, et al.
The Journal of Investigative Dermatology|October 23, 2020
Inverse Correlation of TRIM32 and Protein Kinase C ζ in T Helper Type 2-Biased InflammationZhiping Wang, Yeon Jung Yoo, Rachel De La Torre, et al.
Dermatologic Therapy|October 21, 2022
Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomesEric Simpson, April Armstrong, Mark Boguniewicz, et al.
Dermatology and Therapy|September 22, 2017
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in AdultsAndreas Kuznik, Gaëlle Bégo-Le-Bagousse, Laurent Eckert, et al.
BMC Dermatology|November 7, 2019
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitisEric Simpson, Laurent Eckert, Abhijit Gadkari, et al.
Cytokine|November 6, 2020
Synergistic induction of IL-23 by TNFα, IL-17A, and EGF in keratinocytesBenjamin Ehst, Zhiping Wang, Justin Leitenberger, et al.
The Journal of Dermatological Treatment|March 12, 2026
Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 yearsEric Simpson, Tilo Biedermann, Leon Kircik, et al.
The Journal of Allergy and Clinical Immunology|October 6, 2014
The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trialsJochen Schmitt, Phyllis I Spuls, Kim S Thomas, et al.
Dermatology and Therapy|July 22, 2023
Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis RegistryJonathan I Silverberg, Vivian Y Shi, Andrew Alexis, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
European Journal of Dermatology : EJD|October 27, 2022
Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trialsAndreas Wollenberg, Peter Lio, Elise Kleyn, et al.
Dermatology and Therapy|November 12, 2024
Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b StudyMelinda Gooderham, Emma Guttman-Yassky, Ken Igawa, et al.
The Journal of Investigative Dermatology|October 23, 2020
Inverse Correlation of TRIM32 and Protein Kinase C ζ in T Helper Type 2-Biased InflammationZhiping Wang, Yeon Jung Yoo, Rachel De La Torre, et al.
Dermatologic Therapy|October 21, 2022
Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomesEric Simpson, April Armstrong, Mark Boguniewicz, et al.
Dermatology and Therapy|September 22, 2017
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in AdultsAndreas Kuznik, Gaëlle Bégo-Le-Bagousse, Laurent Eckert, et al.
BMC Dermatology|November 7, 2019
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitisEric Simpson, Laurent Eckert, Abhijit Gadkari, et al.
Cytokine|November 6, 2020
Synergistic induction of IL-23 by TNFα, IL-17A, and EGF in keratinocytesBenjamin Ehst, Zhiping Wang, Justin Leitenberger, et al.
The Journal of Dermatological Treatment|March 12, 2026
Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 yearsEric Simpson, Tilo Biedermann, Leon Kircik, et al.
The Journal of Allergy and Clinical Immunology|October 6, 2014
The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trialsJochen Schmitt, Phyllis I Spuls, Kim S Thomas, et al.
Dermatology and Therapy|July 22, 2023
Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis RegistryJonathan I Silverberg, Vivian Y Shi, Andrew Alexis, et al.
Pageof 8